Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx

5

X.j Myopathy-Myositis-Polymyositis (see also under Xba)

1

May associate with myocarditis (PMID 30790071)

Last update : 26/02/2019
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Atezolizumab
2
Avelumab
1
CTLA4 blocking immunotherapy
3
Camrelizumab
1
Ipilimumab
4
Lambrolizumab
4
Nivolumab
5
PD-1/PD-L1-inhibitors or blocking agents/drugs
5
Pedelizumab
1
Pembrolizumab
5
Tislelizumab
1
Tremelimumab
1
Vaccination - Immunization
2
Vaccines
3
Zimberelimab
1

Publications

Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis.
Internal medicine (Tokyo, Japan) 2018 Aug 01;57;2217-2221 2018 Aug 01
Progressive hypoventilation due to mixed CD8 and CD4 lymphocytic polymyositis following tremelimumab - durvalumab treatment.
Journal for immunotherapy of cancer 2017 Jul 18;5;54 2017 Jul 18
[Unexpected adverse events of immunotherapies in non-small cell lung cancer: About 2 cases].
Revue de pneumologie clinique 2017 Dec;73;326-330 2017 Dec

Powered by

  • ^
  • Contact
  • Cookies
  • About